Friday, November 6, 2026

An important update for nearly 4 lakh retail shareholders of Sammaan Capital; Details here

Date:

Shares of Sammaan Capital Ltd. will be excluded from the Futures & Options (F&O) segment, according to the latest circular issued by the National Stock Exchange.According to the circular, no futures and options contracts of Sammaan Capital will be issued starting July 1, 2026.

However, the existing unexpired contracts of April 2026, May 2026 and June 2026, will continue to remain available for trading till their respective expiry and new strikes would also be introduced in the existing contract months, the NSE circular stated.
Sammaan Capital has been one stock that generally continues to remain in the Futures & Options (F&O) ban, through a given series, exits the ban only when the series ends or close to expiry, and re-enters the F&O ban a day or two after a new series begins.As of Thursday, Sammaan Capital’s shares continue to remain in the F&O ban, which means no new positions can be taken in the stock. The stock had entered the ban at the start of the April series itself and had stayed in the ban since.

Shares of Sammaan Capital ended 0.8% lower on Thursday at ₹155.2. The stock is up 11% over the last one month but is down 20% from its 52-week high levels.

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

Raamdeo Agrawal sees FIIs return as earnings improve and valuations turn attractive

Question Looking at the valuation compression across the market, are...

Stocks to Watch for November 2: Reliance Industries, Jio Platforms, BEL, Vodafone Idea, IOC, M&M and more

From Reliance Industries and Jio Platforms reporting strong quarterly...

Nvidia chief Jensen Huang reportedly targeted in Chinese spy plot | World News

By Jonathan Swan , Maggie Haberman , Ana Swanson...

Anup Bagchi takes charge at HDFC Bank: Can he close the gap with ICICI Bank?

When Anup Bagchi takes charge as MD and CEO...